Provectus Pharmaceuticals Inc. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Provectus Pharmaceuticals Inc.

PVCT 0.0650

+0.2%

Nov 18 12:36 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: boomertree2 who wrote (11961)	5/22/2013 3:11:29 PM
From: Howard Williams	1 Recommendation of 13111

boomertree2, IMO the best (fastest/cheapest) path to accelerated approval or Breakthrough Designation would be via the simplest Phase III design that shows efficacy (with safety) for adequate to support either of those highly desirable options. And the Moffitt data can seal the deal. Argarwala's statement almost explicitly telegraphs that ...... "Right now we consider such a response [the bystander effect] to be a bonus clinically."

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next